EP Wealth Advisors LLC Buys 255 Shares of Sanofi (NASDAQ:SNY)

EP Wealth Advisors LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 5.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,035 shares of the company’s stock after purchasing an additional 255 shares during the quarter. EP Wealth Advisors LLC’s holdings in Sanofi were worth $250,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Rise Advisors LLC lifted its holdings in shares of Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new position in shares of Sanofi during the fourth quarter worth approximately $27,000. Venturi Wealth Management LLC lifted its holdings in shares of Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi during the fourth quarter worth approximately $28,000. Finally, McIlrath & Eck LLC lifted its holdings in shares of Sanofi by 143.3% during the fourth quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after buying an additional 361 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $46.85 on Friday. The business has a fifty day simple moving average of $48.32 and a 200 day simple moving average of $48.48. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $118.52 billion, a price-to-earnings ratio of 23.54, a PEG ratio of 1.48 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $55.72.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, meeting analysts’ consensus estimates of $0.96. The business had revenue of $11.36 billion during the quarter, compared to analyst estimates of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. Sell-side analysts expect that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 6th. Shareholders of record on Friday, May 10th were paid a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date was Thursday, May 9th. Sanofi’s dividend payout ratio is currently 74.37%.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.